Shares of Kala Pharmaceuticals, Inc. (KALA) are surging more than 100% Wednesday morning on the news that the FDA has accepted investigational new drug application for KPI-012, the company's lead product candidate for the treatment of persistent corneal epithelial defect (PCED).
The company plans to initiate Phase 2b study of KPI-012 for the treatment of PCED in the first quarter of 2023.
Additionally, following the FDA's acceptance of the IND application for KPI-012, the company received the remaining $25 million investment under the previously announced private placement financing.
KALA is at $8.66 currently. It has traded in the range of $3.54-$97.00 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.